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Since human epidermal growth factor receptor 2 (HER2) is known to participate with the epidermal growth factor receptor (EGFR)
in mitogenic signalling, we hypothesised that HER2 overexpression might indicate responsiveness to EGFR targeted therapies. MCF7
breast cancer cells transfected with the HER2 gene were subcloned to establish a set of genetically related cell lines expressing graded
levels of HER2 by immunoblot analysis. The subcloned cell lines and parental MCF7 cells were characterised by their growth
characteristics, and cell by cell patterns of EGFR, HER2 and HER3 expression as well as levels of phosphorylated mitogen-activated
protein kinase (MAPK) and AKT by laser scanning cytometry (LSC). Growth inhibition assays were used to characterise response to
EGFR targeted therapy, and to determine the relationship between therapeutic response and levels of tyrosine kinase expression.
The levels of growth inhibition of AG1478 and of the AG1478-trastuzumab combinations were correlated with levels of HER2
expression among the different cell lines. Among EGFR, HER2 and HER3, HER2 overexpression was the best single predictive
marker, but combinations of two markers provided additional predictive information.
British Journal of Cancer (2006) 94, 1144–1153. doi:10.1038/sj.bjc.6603078 www.bjcancer.com
Published online 4 April 2006
& 2006 Cancer Research UK
Keywords: HER2; EGFR; HER3; trastuzumab; targeted therapy; breast cancer
                                           
Human epidermal growth factor receptor 2 (HER2), a member of
the epidermal growth factor receptor (EGFR) family of tyrosine
kinases, is overexpressed in 25–30% of human breast cancers
(Slamon et al, 1987, 1989). It has been implicated in cancer
progression (Yarden, 2001; Nahta and Esteva, 2003), and has been
identified as a prognostic and predictive marker for breast cancer
outcome (Winston et al, 2004). Breast cancers with HER2 gene
amplification and/or protein overexpression have been shown to
be responsive to trastuzumab (Herceptin), a humanised mono-
clonal antibody directed against the extracellular domain of HER2
(Baselga, 2001; Arteaga and Baselga, 2004). Trastuzumab produces
high objective response rates and prolongation of overall survival
as a single agent (Vogel et al, 2002) and in combination with
chemotherapy (Slamon et al, 2001). Several assays, based on
immunohistochemistry (IHC) or fluorescence in situ hybridisation
(FISH), are FDA-approved for the clinical identification of breast
cancer patients who are likely to respond to trastuzumab (Winston
et al, 2004). The clinical usefulness of trastuzumab in breast cancer
may be due in part to the robustness and wide availability of these
standardised assays.
The EGFR is expressed in 15–35% of breast cancers, and is also
associated with a poor prognosis (Thor et al, 2001; Suo et al, 2002).
Agents targeted against the EGFR have been studied extensively in
the laboratory, and several have undergone clinical trials,
including Cetuximab (Erbitux), a humanised monoclonal antibody
directed against the extracellular domain of the EGFR, and the
small molecule tyrosine kinase inhibitors (TKIs) Gefitinib (Iressa/
ZD1839), and Erlotinib (Tarceva/OSI-774). These agents have
demonstrated clinical activity in 8–20% of patients with non-
small-cell lung cancer (NSCLC), especially in a subset of NSCLC
patients whose tumours contain mutations involving the ATP
binding pocket of the EGFR (Lynch et al, 2004; Paez et al, 2004).
Although preclinical cell culture and xenograft studies suggest that
EGFR targeted therapies hold promise for certain subtypes of
breast cancer, clinical trials to date have shown responses in less
than 10% of patients (Konecny et al, 2003; Arteaga and Truica,
2004; Kaklamani and O’Regan, 2004).
Tumour EGFR expression has not proven to be a useful
predictive marker of clinical response to EGFR-targeted therapies
(Johnson and Arteaga, 2003; Campiglio et al, 2004). There is no
clear correlation between EGFR expression and response to
Erlotinib, Gefitinib or Cetuximab efficacy in NSCLC or colorectal
cancer (Saltz et al, 2001; Fukuoka et al, 2003; Johnson and Arteaga,
2003; Perez-Soler, 2004; Saltz et al, 2004; Noberasco et al, 2005).
This may be due in part to the lack of a standardised protocol and
grading system for EGFR expression in clinical samples (Noberasco
et al, 2005; Younes, 2005), to technical limitations that are inherent
in immunohistochemical methods (Younes, 2005), or, perhaps, to
an intrinsically poor correlation between the level of EGFR
expression and therapeutic response (Arteaga and Baselga, 2004).
Robust predictive markers are needed in order to identify the
relatively small subsets of patients whose tumours are likely to
respond to EGFR-targeted therapies (Baselga, 2002; Castro, 2002;
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sArteaga and Baselga, 2003). Candidate markers include phos-
phorylated EGFR (Arteaga and Baselga, 2003; DiGiovanna et al,
2005), and phosphorylated effector molecules downstream of the
EGFR, such as the mitogen-activated protein kinase (MAPK) and
protein kinase B (AKT) (Lynch et al, 2004; Han et al, 2005).
However, there are concerns about the stability of phosphorylated
proteins in primary tumour samples prior to fixation, and
protocols for the collection and processing of clinical material
for phosphorylated protein analysis have yet to be validated and
standardised (Baselga, 2002; Lynch et al, 2004).
Human epidermal growth factor receptor 2 and the EGFR are
known to heterodimerise with one another to drive mitogenic
signalling pathways, and heterodimerisation has been shown to
inhibit internalisation and degradation of the EGFR (Lenferink
et al, 1998). Thus, receptor interactions involving HER2 may play
key roles in breast cancer cells that both overexpress HER2 and
express the EGFR. Epidermal growth factor receptor inhibitors are
effective in blocking HER2 mediated signalling in HER2 over-
expressing breast cancer cell lines that co-express the EGFR, and
combinations of EGFR and HER2 targeted agents have been shown
to have additive or synergistic effects on growth inhibition
(Moasser et al, 2001; Moulder et al, 2001; Normanno et al, 2002;
Anido et al, 2003). A recent clinical study has suggested that the
adverse prognostic value of HER2 overexpression occurs only with
HER2 activation or EGFR co-expression in breast cancer
(DiGiovanna et al, 2005). In another recent clinical study in
NSCLC, increased HER2 gene copy number was associated with
sensitivity to gefitinib in EGFR-positive patients (Cappuzzo et al,
2005).
To investigate the potential role of HER2 as a predictive marker
for responsiveness to EGFR targeted therapies, we developed a
series of MCF7 breast cancer cell line subclones that express
graded levels of HER2. Despite heterogeneity of levels of EGFR and
HER3 expression, levels of MAPK and AKT phosphorylation, and
overall growth rates among the different cell lines, the inhibition of
tumour cell proliferation by AG1478 alone or in combination with
trastuzumab was correlated with levels of expression of HER2.
MATERIALS AND METHODS
Generation of HER2 transfectant cell lines
cDNA encoding human HER2 was excised from a pLXSN retroviral
expression construct (Riese et al, 1995) by digestion with Xho1,
and inserted into the mammalian expression vector pcDNA 3.1
encoding geneticin resistance. Plasmids containing the correctly
oriented insert were identified by restriction digest mapping
followed by sequencing of the 50 and 30 ends of the insert. The
HER2-pcDNA 3.1 construct was transfected into the breast cancer
cell line MCF7 utilising a BioRad Gene Pulser Xcell. MCF7 cells
were grown to 80–90% confluence and fed the day before
transfection. Cells were trypsinised, centrifuged, and resuspended
at a concentration of 1 10
7cellsml
 1 in culture medium. A
measure of 400ml of the cell suspension was mixed with 100mgo f
DNA construct in a 0.4cm gap electroporation cuvette (BioRad,
Hercules, CA, USA), and incubated at 41C for 10min on ice. The
transfection mixture was electroporated at 220V and 950mF and
plated into two 100mm tissue culture plates. The transfected cells
were cultured overnight for recovery and then cultured in the
appropriate selective media for 4–8 weeks. Resultant colonies or
cell pools were subcloned by colony transfer and plating of cell
pools into 24-well plates at an average ratio of 2 cells per well.
Individual neomycin resistant clones were expanded and assayed
for HER2 expression by immunoblot analysis. SKBR3 (an
unrelated HER2 overexpressing breast cancer cell line) was used
as an independent comparative reference for HER2 expression in
the immunoblots.
Cell culture and preparation
JC 1939, MCF7, and SKBR3 breast cancer cell lines were
maintained in RPMI 1640 containing 100Uml
 1 penicillin and
streptomycin, 0.25mgml
 1. amphotericin B, and 10% fetal bovine
serum (FBS). The HER2 transfected clonal cell lines were cultured
in the same media supplemented with 500mgml
 1 geneticin.
Immunoblot analysis
Cell lysate (50mg) was subject to SDS–PAGE on 4–20% tris/
glycine gels, transferred onto nitrocellulose filters, and blocked for
0.5h in TTBS (100mM Tris, pH 7.5, 0.9% NaCl, 0.1% Tween-20)
with 5% nonfat dry milk. A monoclonal antibody against HER2
(clone CB11, Novacastra Laboratories, Newcastle-upon-Tyne, UK)
was used at a 1:1000 dilution. The secondary antibody was goat
anti-mouse horseradish peroxidase (HRP) conjugated antibody
(Santa Cruz Biotechnology), and was used at a 1:1000 dilution.
Antibody signal was visualised using the SuperSignal West Pico
Chemiluminescent Substrate (Pierce) exposed to Kodak BioMax
XAR film. Densitometry was performed using a Personal
Densitometer SI (Molecular Dynamics), and the data were
analyzed using Scion Image for Windows (Scion Corporation,
Medford, MA, USA).
Laser scanning cytometry (LSC) analysis
For LSC analysis, cell lines plated into 75cm
2 flasks at
2.5 10
6cellsflask
 1 and harvested in log phase growth by
trypsinisation were treated with cold (41C) 5mM dithiothreitol
(DTT) for 15min at room temperature to reduce clumping and
fixed in 0.5% paraformaldehyde and 70% methanol as described
previously (Pollice et al, 1992). Aliquots of 2 10
4cells from each
of the cell lines were filtered through 64mm nylon mesh (Small
Parts), and centrifuged at 200g for 2min. For EGFR family
member analysis, monoclonal antibodies against HER2 (clone
CB11, Novacastra Laboratories), EGFR (clone EGFR.1, BD
Pharmingen, San Diego, CA, USA), and HER3 (clone Ab 5,
Oncogene Research Products, La Jolla, CA, USA), directly
conjugated to FITC, PE and Cy5, respectively, were used at a
1:10 dilution in a 1-h incubation at room temperature in the dark.
For the phosphorylated (P) MAPK and AKT analysis, monoclonal
antibodies against P-MAPK (clone E10, Cell Signaling Technology,
Beverly, MA, USA) and P-AKT (clone 4E2, Cell Signaling
Technology) directly conjugated to Cy5 and Cy3, respectively,
were used. Cell suspensions were washed 1  with PBS and
resuspended in 100mlo f4 0,6-diamidino-2-phenylindole (DAPI)
(Sigma) at a final concentration of 1mgml
 1 in vv
 1 1:1
glycerol:PBS. 100ml of cell suspension was pipetted into a
HybriWell chamber (22 22 0.15mm
3) (Schleicher&Schuell)
affixed to precleaned glass microscope slides. Fluorescence
measurements were made using a laser scanning cytometer
(LSC) (CompuCyte) with the WinCyte (version 3.6) program,
equipped with an air-cooled violet diode laser emitting at a
wavelength of 405nm, an air-cooled argon laser emitting at a
wavelength of 488nm, and an a HeNe laser emitting at
a wavelength of 633nm. DAPI fluorescence was measured using
a 463/39nm band pass filter, FITC fluorescence was measured
using a 530/30nm band pass filter with a 555-nm dichroic long
pass filter, CY3 fluorescence was measured using a 580/30-nm
band pass filter with 605-nm dichroic long pass filter and CY5
fluorescence was measured using a 650-nm long pass filter with a
full mirror. A fixed scan area of 1.6 10
8mm
2 centred on the
HybriWell chamber was used with all samples. DNA was used as
the contouring parameter with a threshold of 700 and 30 pixels
added to threshold. For quantitation of EGFR, HER2 and HER3 in
molecules per cell, the reference cell line JC 1939 was subjected to
ELISAs (Oncogene Science, Carpenteria, CA, USA) with the
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sappropriate antibodies. Fluorescence signal in each cell line from
LSC analysis was normalised to the signal from JC 1939 to
determine molecules per cell.
Proliferation assays/inhibitor analysis
The EGFR inhibitor AG1478 was purchased from Calbiochem, La
Jolla, CA, USA, and was stored at  201C as a 10mM stock in
DMSO. Trastuzumab was a gift from Genentech. Cell stocks were
grown to 80% confluence, trypsinised, and plated in triplicate into
12-well tissue culture plates at 2 10
4cellswell
 1. The following
day, duplicate wells (for day 0 counts) were trypsinised and each
well was counted in triplicate with a haemocytometer. The
remaining wells were fed every other day with regular cell culture
media supplemented with appropriate inhibitor or DMSO as
vehicle control. On day 6, the remaining wells were trypsinised and
counted in triplicate with a hemocytometer, and the data were
graphed in Excel.
Statistical analysis
Statistical analyses were performed using SPSS version 12.0 for
Windows. Human epidermal growth factor receptor 2 expression,
cell growth and drug treatment data were analyzed by one-way
ANOVA followed by a two-sided Dunnett’s test post hoc for the
determination of differences between groups. Pearson correlation
coefficients of linear regression were calculated for  log of
surviving cell fraction vs relative HER2 expression.
The combination index (CI) for drug effect in each cell line was
calculated from the surviving cell fractions of cells treated with
each drug alone, SFA and SFB, and the surviving cell fractions of
cells treated with the drug combination, SFAB, where CI¼SFAB/
(SFA SFB). Triplicate analyses were subjected to two-sided
statistical tests (1-group, two-tailed test with degrees of free-
dom¼2) to determine if the mean CI value for each cell line was
significantly different from a CI of 1.0 at the Po0.05 level. Synergy
was defined by a CI value that was significantly 41.0, and
antagonism was defined by a CI value significantly greater than
1.0. Effects were considered additive if the CI was not significantly
different from 1.0.
Prediction of treatment outcomes
Least-squares linear regression analysis was applied to correlate
protein expression levels with efficacy ratios of trastuzumab and
AG1478 on the parental MCF7 and HER2 expressing subclones.
Mean expression of EGFR, HER2 and HER3 were derived from
cell-based measurements of molecules per cell by LSC. Drug
efficacy ratios were derived for each treatment by taking one
minus the ratio of cells counted following treatment to cells
counted without treatment. A linear regression model was defined
to relate efficacy ratio (k) to mean expression levels of EGFR,
HER2 and HER3 using the formula
k   a1½EGFR þa2½HER2 þa3½HER2 
Constants a1, a2 and a3 were derived to provide a least-squares fit
between observed and predicted efficacy ratios across the cell lines
examined. Least-squares regression was further attempted for each
of the three assayed genes in isolation, using models of the form
k   ~ a1½EGFR 
k   ~ a2½HER2 
k   ~ a3½HER3 
where each of the a ˜1, a ˜2 and a ˜3 constants was derived to provide a
least-squares best-fit between the observed efficacy ratios and
those predicted from the single gene in isolation. Each of these
linear regression analyses was tested by leave-one-out cross
validation. For each cell line, parameters were fit without using
the data provided by that cell line and the efficacy ratio for the
missing cell line was predicted from the derived parameters. The
root mean square errors of the predictions were assessed for all
regression analyses with and without the cross-validation.
RESULTS
Generation of MCF7 subclones that overexpress HER2 at
graded levels, and analysis of growth characteristics
The MCF7 breast cancer cell line was transfected with a pcDNA 3.1
construct encoding human HER2 that was derived from a
retroviral construct (Riese et al, 1995), and HER2 expressing
clones were identified by immunoblot analysis (Figure 1A). Clones
were isolated that overexpress low (NH33, NH42 and NH77),
intermediate (NH13, NH29 and NH47), or high (NH131 and NH27)
levels of HER2 by comparison with the parental MCF7 line. The
cell lines with the highest level of HER2 expression exhibit levels
that approach that found in the endogenously high HER2
overexpressing SKBR3 cell line. Quantitative densitometry mea-
surements on HER2 immunoblots from multiple passages of these
clones are shown in Figure 1B. The growth rates and levels of
HER2 expression of the subclones were monitored at each passage
to ensure stability.
The relative growth rates of the transfected cell lines are shown
in Figure 1C. The HER2 transfected clones all grow more slowly
than the reference parental MCF7 line. This is consistent with
previous studies that have demonstrated a decrease in the growth
rate of MCF7 cells with HER2 transfection and overexpression
(Giani et al, 1998; Huang et al, 2002). The low HER2 over-
expressing cell lines show a 45% reduction in growth rate from the
parental MCF7, and the intermediate HER2 expressing clones
exhibit an 85% reduction in growth rate (Po0.05). The subclones
in the high HER2 overexpressing group exhibit higher growth rates
than the subclones with intermediate levels of HER2 expression.
These findings do not support a monotonic relationship between
mean HER2 expression level and growth rate.
Cell by cell correlation of HER2, EGFR and HER3
expression levels in the HER2 transfectants
Parental MCF7 cells and HER2 transfected MCF7 subclones were
grown to subconfluence, and fed with normal culture media 24h
prior to trypsinisation and cell fixation. The fixed cells were
stained with fluorochrome conjugated antibodies against the
EGFR, HER2 and HER3 and analyzed by LSC. The results,
expressed in molecules per cell and correlated cell by cell, are
shown in Figure 2. The HER2 level for each cell is plotted on the
abscissa, and the HER3 level for each cell is plotted on the
ordinate. The EGFR level for each cell line is shown using a series
of colour-coded symbols as indicated in the figure legend. In all
cell lines, there is a correlation between levels of HER2/cell and
levels HER3/cell in the same cells, as well as between HER2/cell
and EGFR/cell, and EGFR/cell and HER3/cell (see Supplementary
Table 1S).
It is apparent that despite the overall correlations among levels
of HER2, EGFR and HER3 in the same cells, there are substantial
differences among the different subclones with respect to the
ranges of levels of expression of these cell constituents. Human
epidermal growth factor receptor 2 levels are lowest in the parental
MCF7 cell line and highest in NH27 cells, but NH27 cells have
neither high levels of HER3 nor the highest levels of EGFR per cell.
In most of the MCF7 subclones that contain high EGFR
overexpressing cells, the cells with EGFR levels exceeding
80000molecules per cell exhibit only moderately elevated levels
of HER2 (mostly in the range of 200000–600000molecules per
HER2 expression in EGFR targeted therapies
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scell). However, in NH27 cells, among the few that exhibit EGFR
levels in excess of 80000molecules per cell, most also have HER2
levels that exceed 600000molecules per cell. Thus, across
subclones, there is a relationship between levels of EGFR
expression and HER3 expression per cell that is worth pursuing
(see below), but there does not appear to be a strict quantitative
relationship between increased EGFR levels and/or HER3 levels on
the one hand and increasing HER2 levels on the other.
Cell by cell levels of P-MAPK and P-AKT
Parental MCF7 cells and HER2 transfected MCF7 subclones were
prepared for LSC, and stained with antibodies against the
phosphorylated forms of MAPK and AKT. Correlated cellular
levels of P-MAPK and P-AKT were determined by LSC (Figure 3).
Quantitative cellular levels of each phospho-protein are expressed
in arbitrary units, where mean cellular levels obtained in
concomitantly run aliquots of stored reference cells are assigned
values of 10000 arbitrary units per cell. Mean levels of P-AKT
range from B43000 units per cell in NH131 cells to B87000 units
per cell in NH27 cells. Across cell lines, there is no strong
correlation between mean P-AKT level per cell and HER2 level
(r¼0.078, P¼0.868; see Supplementary Figure 1S).
There was considerable variation in levels of P-MAPK per cell,
both within and among the different cell lines (Figure 3). Across
cell lines, mean levels of P-MAPK per cell varied from B28000
units per cell in NH27 cells to B131000 units per cell in NH47
cells. There was no correlation between mean P-MAPK level per
cell and HER2 level across cell lines (r¼ 0.067, P¼0.886; see
Supplementary Figure 1S).
Within individual cell lines, the simultaneous measurement of
P-MAPK and P-AKT in each cell by LSC reveals a strong
correlation between the cellular levels of these two phospho-
proteins (Figure 3). However, the slopes of the regression vary
from cell line to cell line.
Effects of AG1478 and trastuzumab on cell proliferation
The effects of 0.5mM AG1478, 1mgml
 1 trastuzumab, and a
combination of 0.5mM AG1478 and 1mgml
 1 trastuzumab on cell
proliferation are shown in Figure 4A. These drug concentrations
were estimated to fall within a clinically achievable range (Hidalgo
et al, 2001; Pegram et al, 2004), and showed activity in preliminary
dose response studies (see Supplementary Figure 2S). In trans-
fected MCF7 cell subclones with modest increases in HER2
overexpression (NH33, NH42 and NH77), the effects of trastuzu-
mab on cell proliferation (white bars, Figure 4A) are not
significantly different from its effects on parental MCF7 cells.
Trastuzumab decreases cell proliferation in the intermediate HER2
overexpressing group by an average of 17% in comparison with
parental MCF7 cells (P¼0.005). In the high HER2 expressing
group, trastuzumab produced an average decrease in cell
proliferation that is 24% greater than in parental MCF7 cells
(P¼0.004), but the difference in the effects of trastuzumab on
intermediate and high HER2 overexpressing MCF7 subclones is
not statistically significant (P¼0.244).
AG1478 treatment does not substantially inhibit the growth of
parental MCF7 or the low HER2 overexpressing subclones (black
bars, Figure 4A). Compared to parental MCF7, AG1478 has a 25
and 36% greater mean inhibition of proliferation on the
intermediate (P¼0.05) and high (P¼0.007) HER2 expressing
clones, respectively. However, the difference in response between
the intermediate and high HER2 expressing clones is not
statistically significant (P¼0.077).
Combined treatment of these cell lines with both AG1478 and
trastuzumab (grey bars, Figure 4A) produces a significantly greater
inhibition of proliferation than that of either agent alone only in
cell lines with intermediate and high levels of overexpression of
HER2. The drug combination produces greater inhibition of cell
proliferation in the intermediate and high HER2 expressing clones
in comparison with AG1478, the best single agent for these cell
lines (Po0.05).
When all of the cell lines in the panel are considered together,
there are strong correlations between log growth inhibition by
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Figure 1 Stable HER2 expression levels and growth characteristics of
HER2 transfected MCF7 subclones. (A) HER2 expression by immunoblot
analysis in HER2 cDNA vector transfected MCF7 cell lines overexpressing
low (LOW), intermediate (INT) and high (HIGH) levels of HER2
compared to parental MCF7 and SKBR3 breast cancer cell lines. The
position of the molecular weight marker is shown on the right. (B)
Exposures from three separate immunoblots of the MCF7 subclones were
subjected to densitometry, and density values were normalised to the
HER2 value from the NH27 cell line. The means of the HER2 signals from
the LOW, INT and HIGH groups are statistically significantly different from
one another and from the MCF7 signal (Po0.01 in each comparison),
except for the MCF7 vs the LOW HER2 expressing subclones (P¼0.462).
(C) Total cell number relative to control MCF7 after 6 days of growth for
the HER2 transfected MCF7 subclones. Results of three independent
experiments were normalised to the mean of parental MCF7 cells. Bars,
7s.e.
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seach drug individually or in combination and mean levels of HER2
expression in the cell lines (Figure 4B). There is a strong
correlation between the degree of cell growth inhibition by
trastuzumab and HER2 expression level (r¼0.945, P¼0.0001;
Figure 4B, left panel), between AG1478 and HER2 expression level
(r¼0.934; P¼0.0002; Figure 4B, middle panel), and between the
degree of cell growth inhibition by combined treatment (AG1478
plus trastuzumab) and HER2 expression level (r¼0.909,
P¼0.0006; Figure 4B, right panel).
To further characterise the interaction between the effects of
AG1478 and trastuzumab, the CI was calculated for each cell line
(Table 1). Overall, the CIs suggest that the combined drug effect is
additive, except in the NH27 cell line, where synergy was clearly
demonstrated. However, since the overall effects of these agents are
small in the low HER2 expressing lines, the CI results may be
difficult to interpret in these cell lines.
Prediction of efficacy of AG1478, trastuzumab and the
combination of AG1478 and trastuzumab from multiple
receptor expression data
We applied least-squares regression to find a best-fit linear model
of drug efficacy as a function of mean EGFR, HER2 and HER3
expression levels derived from LSC measurements of parental
MCF7 and HER2 transfected subclones (Table 2). Using the three
receptor levels individually as predictors of trastuzumab efficacy
with leave-one-out cross-validation, the root mean square predic-
tion errors are 0.099 for HER2 alone, 0.123 for EGFR alone, and
MCF7 NH33
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NH131 NH27
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Figure 2 Laser scanning cytometry analysis of EGFR, HER2 and HER3 expression in parental MCF7 and MCF7 HER2 transfected subclones. Parental
MCF7 and HER2 transfected subclones were trypsinised, stained with fluorochrome-conjugated antibodies directed against the EGFR, HER2 and HER3, and
subjected to multiparameter LSC analysis. Correlated cell-by-cell fluorescence measurements are shown with HER2 expression plotted on the abscissa,
HER3 expression plotted on the ordinate, and EGFR expression plotted as object/colour coded: EGFR o20000moleculescell
 1 (black diamonds), EGFR
20000 to o40000molecules per cell (open red squares), EGFR 40000 to o80000molecules per cell (open green triangles), EGFR480000molecules
per cell (open blue squares). All receptor level values are expressed as receptor numbers per cell, based on known mean values (determined independently
by ELISA) in a concomitantly run reference cell line, and corrected for autofluorescence, cell aggregates and fluorescence channel crosstalk.
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s0.159 for HER3 alone. Thus, HER2 is the best individual marker for
the prediction of trastuzumab efficacy in these cell lines. With
regard to predicting for AG1478 effect, root mean square errors are
0.192 for HER2 alone, 0.233 for EGFR alone, and 0.286 for HER3
alone, suggesting that HER2 expression level is also the best single
predictor of AG1478 efficacy in these cell lines. Human epidermal
growth factor receptor 2 is also the best individual predictor for
combined drug efficacy.
Overall, the smallest root mean square error for prediction of
trastuzumab efficacy (0.089) was achieved using a combination of
HER2 and HER3 expression levels. Interestingly, the overall
smallest root mean square error for prediction of AG1478 efficacy
(0.180) is achieved using a combination of EGFR and HER3
expression levels. Predictions using all three receptor expression
levels together result in errors that were not as low as those derived
from the best individual or two-receptor predictions, suggesting
that the data set may be too small to draw robust inferences from
the three-protein model.
DISCUSSION
It is generally agreed that there is a need for better clinical
biomarkers for response to EGFR targeted therapy (Baselga, 2002;
Castro, 2002; Arteaga and Baselga, 2003). Overall clinical response
rates to EGFR targeted therapy in many of the common human
solid tumours are generally low, often in the range of 5–20%
(Castro, 2002; Fukuoka et al, 2003; Kris et al, 2003). Many patients
whose tumours express EGFR fail to respond to EGFR targeted
therapy, and conversely, patients who respond may have tumours
that do not exhibit EGFR expression (Noberasco et al, 2005;
Younes, 2005). Preclinical studies in tissue culture and in
xenografts using cancer cell lines with known EGFR expression
have shown that EGFR overexpression itself might not be a useful
predictive marker for response to EGFR targeted therapy (Sirotnak
et al, 2000; Ciardiello et al, 2000, 2001; Moasser et al, 2001;
Wakeling et al, 2002; Campiglio et al, 2004). In this study, we show
that growth inhibition in response to AG1478, a targeted inhibitor
of the EGFR, and AG1478 in combination with the HER2 targeted
antibody trastuzumab, is correlated with increased HER2 expres-
sion levels. The largest effects of these therapies are seen in the cell
lines expressing the highest levels of HER2.
Human epidermal growth factor receptor 2 is known to
heterodimerise preferentially with the EGFR (Graus-Porta et al,
1997), potentiate mitogenic signalling by increasing ligand
affinities of the EGFR, and protect the EGFR from degradation
(Tzahar et al, 1996; Lenferink et al, 1998). This could provide a
mechanistic explanation for our findings. In support of this
premise, EGFR and HER2 co-expression has been linked to a more
aggressive clinical phenotype and to poor prognosis in breast
cancer (Thor et al, 2001; Suo et al, 2002). Preclinical studies in
breast cancer cell lines that overexpress HER2 show that combined
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Figure 3 Laser scanning cytometry analysis of P-MAPK and P-AKT levels on a cell-by-cell basis in control and HER2 transfected MCF7 subclones. For each
cell, P-MAPK level per cell is plotted on the ordinate and P-AKT level in the same cell is plotted on the abscissa. Values are corrected for autofluorescence,
cell aggregates and cross talk. The mean fluorescence values for P-MAPK and P-AKT, the slope, and correlation coefficient (r) for each cell line are shown.
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sEGFR and HER2 inhibition may be more effective than treatment
with single agents, regardless of EGFR expression level (Moasser
et al, 2001; Moulder et al, 2001; Normanno et al, 2002; Anido et al,
2003).
Our panel of HER2-transfected subclones was intended to
provide the opportunity to study the effects of targeted therapeutic
agents in a family of cell lines that have few overall genotypic
differences, and that express graded levels of HER2 protein.
Nonetheless, there are differences among these subclones in
quantitative levels of intracellular co-expression of key proteins,
including HER2, EGFR and HER3 (Figure 2), and relative levels of
co-expression of P-ERK and P-AKT per cell, which also vary from
cell line to cell line (Figure 3). Thus, we demonstrate a direct
relationship between the degree of efficacy of anti-EGFR regimens
and the levels of HER2 expression in breast cancer cell lines
(Figure 4A and B). This supports the case for investigating the
potential clinical role of HER2 overexpression as a predictive
marker for response to anti-EGFR therapy in human cancers.
Other cell constituents might also predict response to anti-EGFR
therapy, and some might provide independent predictive informa-
tion. The data on EGFR, HER2 and HER3 expression levels by LSC
support this possibility. We have noted that high cellular levels of
EGF receptor are often accompanied by high levels of HER3 in the
same cells (Figure 2). The linear regression analysis shows that
although increased expression of HER2 is the best single predictor
for responsiveness to AG1478 or the AG1478-trastuzumab
−Log surviving cell fraction
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Figure 4 Effects of AG1478, trastuzumab, and a combination of AG1478 and trastuzumab on the growth of control cell lines and HER2 transfected
subclones, and correlation of HER2 expression with drug efficacy. (A) Parental MCF7 control cell lines and the HER2 transfected MCF7 subclones were
plated into 12-well tissue culture plates and treated with 1mgml
 1 trastuzumab (white bars), 500nM AG1478 (black bars), or a combination of both (grey
bars) for 5 days. On day 6, the cells were trypsinised, counted and the cell number from drug treated samples were normalised with respect to control cells
treated with vehicle only (DMSO and human IgG). (B) Mean HER2 expression level in the cell lines, normalised with respect to the HER2 content of the
NH27 cell line, was correlated to –log of surviving cell fractions from individual drug treatments (Trastuzumab, and AG1478) and combined drug treatments
(TrastuzumabþAG1478).  log of surviving cell fraction is plotted on the ordinate, and mean HER2 expression is plotted on the abscissa. The correlation
coefficient (r) and P-value for each correlation are shown. The results are from at least three independent experiments. Bars¼795% CI.
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combination of predictors for the efficacy of AG1478 or combined
AG1478-trastuzumab is increased expression of the EGFR and
HER3 (Table 2).
Of course, one cannot assume that results obtained on cell lines
in vitro can be translated directly into the clinic. Additional
support from experimental studies in vivo would be highly
desirable. Such studies would require the development and
validation of a suitable panel of tumour lines that stably
overexpress graded levels of HER2 in vivo.
Several published clinical studies suggest that our findings in
breast cancer cell lines might be of some relevance in the clinical
setting. In a recent study of breast cancer patients, 35% of 306
HER2-overexpressing tumours were found to express EGFR
Conversely, 87% of EGFR-overexpressing tumours were found to
overexpress HER2 as well (DiGiovanna et al, 2005). In a recent
paper involving NSCLC patients, clinical responses to gefitinib (an
anti-EGF receptor agent) were shown to be correlated with HER2
overexpression/amplification in EGF receptor-positive patients
(Cappuzzo et al, 2005). It would seem reasonable to investigate the
possibility of a relationship between HER2 status and response to
anti-EGFR therapy in patients with breast cancer as well, based on
our findings in breast cancer cell lines that responses to
trastuzumab and AG1478 alone or in combination are correlated
with high levels of HER2 expression.
In summary, we show that in human breast cancer cell lines
increased levels of HER2 expression alone are associated with
increased effectiveness of anti-EGFR therapy, alone or in
combination with anti-HER2 therapy, and that the combination
of EGFR and HER3 overexpression may be an even better
predictor of response. This would suggest the possibility that
HER2 overexpression alone and/or the combination of EGFR and
HER3 expression levels might be useful clinical markers for
response to EGFR and combined EGFR–HER2 targeted therapy in
patients with breast cancer.
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